ClinicaliQ Trial Snapshot
- ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) — Active Not Recruiting • Phase II • Oncology • NCT05601752.
- SURPASS-3 Trial Summary.
- A phase 2 trial testing a new cell therapy alone or combined with immunotherapy in women with recurrent ovarian cancer.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian cancer positive for MAGE-A4. Conditions: Ovarian Cancer Interventions: Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab Lead Sponsor: USWM CT, LLC Planned Enrollment: 66 participants